Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Willis, Jason, Lefterova, Martina I., Artyomenko, Alexander, Kasi, Pashtoon Murtaza, Nakamura, Yoshiaki, Mody, Kabir, Catenacci, Daniel V.T., Fakih, Marwan, Barbacioru, Catalin, Zhao, Jing, Sikora, Marcin, Fairclough, Stephen R., Lee, Hyuk, Kim, Kyoung-Mee, Kim, Seung Tae, Kim, Jinchul, Gavino, Danielle, Benavides, Manuel, Peled, Nir, Nguyen, Timmy, Cusnir, Mike, Eskander, Ramez N., Azzi, Georges, Yoshino, Takayuki, Banks, Kimberly C., Raymond, Victoria M., Lanman, Richard B., Chudova, Darya I., Talasaz, AmirAli, Kopetz, Scott, Lee, Jeeyun, Odegaard, Justin I.·2019·Clinical Cancer Research

Abstract

Purpose: To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing. Experimental Design: Pan-cancer MSI detection using Guardant360 was analytically validated according to established guidelines and clinically validated using 1,145 cfDNA samples for which tissue MSI status based on standard-of-care tissue testing was available. The landscape of cfDNA-based MSI across solid tumor types was investigated in a cohort of 28,459 clinical plasma samples. Clinical outcomes for 16 patients with cfDNA MSI-H gastric cancer treated with immunotherapy were evaluated. Results: cfDNA MSI evaluation was shown to have high specificity, precision, and sensitivity, with a limit of detection of 0.1% tumor content. In evaluable patients, cfDNA testing accurately detected 87% (71/82) of tissue MSI-H and 99.5% of tissue microsatellite stable (863/867) for an overall accuracy of 98.4% (934/949) and a positive predictive value of 95% (71/75). Concordance of cfDNA MSI with tissue PCR and next-generation sequencing was significantly higher than IHC. Prevalence of cfDNA MSI for major cancer types was consistent with those reported for tissue. Finally, robust clinical activity of immunotherapy treatment was seen in patients with advanced gastric cancer positive for MSI by cfDNA, with 63% (10/16) of patients achieving complete or partial remission with sustained clinical benefit. Conclusions: cfDNA-based MSI detection using Guardant360 is highly concordant with tissue-based testing, enabling highly accurate detection of MSI status concurrent with comprehensive genomic profiling and expanding access to immunotherapy for patients with advanced cancer for whom current testing practices are inadequate. See related commentary by Wang and Ajani, p. 6887

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1324

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 239

Metadata

Authors
Willis, J., Lefterova, M. I., Artyomenko, A., Kasi, P. M., Nakamura, Y., Mody, K., Catenacci, D. V. T., Fakih, M., Barbacioru, C., Zhao, J., Sikora, M., Fairclough, S. R., Lee, H., Kim, K.-M., Kim, S. T., Kim, J., Gavino, D., Benavides, M., Peled, N., Nguyen, T., Cusnir, M., Eskander, R. N., Azzi, G., Yoshino, T., Banks, K. C., Raymond, V. M., Lanman, R. B., Chudova, D. I., Talasaz, A., Kopetz, S., Lee, J., & Odegaard, J. I.
Venue
Clinical Cancer Research
Published
2019-12-01
Volume
25
Issue
23
Pages
7035-7045
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2965346296
Cited by
239
References
9
FWCI
8.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1324
The paper
Willis, J., Lefterova, M. I., Artyomenko, A., Kasi, P. M., Nakamura, Y., Mody, K., Catenacci, D. V. T., Fakih, M., Barbacioru, C., Zhao, J., Sikora, M., Fairclough, S. R., Lee, H., Kim, K.-M., Kim, S. T., Kim, J., Gavino, D., Benavides, M., Peled, N., . . . Odegaard, J. I. (2019). Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.